SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study

被引：0

作者：

Qin, Shuqui ^{[1
]}

Li, Jin ^{[2
]}

Zhou, Aiping ^{[3
]}

Zhang, Yanqiao ^{[4
]}

Yuan, Xianglin ^{[5
]}

Zhu, Liangjun ^{[6
]}

Qin, Baoli ^{[7
]}

Zeng, Shan ^{[8
]}

Shen, Lin ^{[9
]}

Yuan, Ying ^{[10
]}

Wang, Weibo ^{[11
]}

Liang, Jun ^{[12
]}

Zhang, Xianwen ^{[13
]}

Ye, Feng ^{[14
]}

Chen, Ping ^{[15
]}

Wang, Huaizhang ^{[16
]}

Yu, Zhenyan ^{[17
]}

Yue, Lu ^{[18
]}

Fang, Yong ^{[19
]}

Xiong, Jianping ^{[20
]}

Yang, Jianwei ^{[21
]}

Wan, Yiye ^{[22
]}

Yin, Xianli ^{[23
]}

Wang, Wenling ^{[24
]}

Xu, Nong ^{[25
]}

Wang, Xiaohong ^{[26
]}

Xiao, Zemin ^{[27
]}

Su, Huafang ^{[28
]}

Wang, Ying ^{[29
]}

Gu, Kangsheng ^{[30
]}

Tu, Shuiping ^{[31
]}

Wang, Zishu ^{[32
]}

Liu, Bo ^{[33
]}

Hu, Xiaohua ^{[34
]}

Liu, Weixian ^{[35
]}

Li, Xiaofeng ^{[36
]}

机构：

[1] Nanjing Jiangning Hosp, Dept Oncol, Nanjing, Jiangsu, Peoples R China

[2] Shanghai East Hosp, Dept Med Oncol, 1,800 Yuntai Rd, Shanghai 200123, Peoples R China

[3] Chinese Acad Med Sci, Canc Hosp, Dept Med Oncol, Beijing, Peoples R China

[4] Harbin Med Univ, Canc Hosp, Dept Pathol, Harbin, Heilongjiang, Peoples R China

[5] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Med Oncol, R China, Wuhan, Hubei, Peoples R China

[6] Jiangsu Canc Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China

[7] Liaoning Canc Hosp & Inst, Dept Gastroenterol, Shenyang, Liaoning, Peoples R China

[8] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China

[9] Beijing Canc Hosp, Dept Med Oncol, Beijing, Peoples R China

[10] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[11] Shandong Prov Hosp, Dept Chemotherapy, Jinan, Peoples R China

[12] Peking Univ, Int Hosp, Dept Med Oncol, Beijing, Peoples R China

[13] Northern Jiangsu Peoples Hosp, Dept Med Oncol, Yangzhou, Jiangsu, Peoples R China

[14] Xiamen Univ, Affiliated Hosp 1, Dept Med Oncol, Xiamen, Fujian, Peoples R China

[15] Ningxia Med Univ, Gen Hosp, Dept Med Oncol, Yinchuan, Ningxia, Peoples R China

[16] Henan Canc Hosp, Dept Integrated Chinese & Western Med, Zhengzhou, Henan, Peoples R China

[17] Mudanjiang Tumor Hosp, Dept Med Oncol, Mudanjiang, Heilongjiang, Peoples R China

[18] Qingdao Municipal Hosp Grp, Dept Oncol, Qingdao, Shandong, Peoples R China

[19] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[20] Nanchang Univ, Affiliated Hosp 1, Dept Med Oncol, Nanchang, Jiangxi, Peoples R China

[21] Fujian Canc Hosp, Dept Abdominal Oncol, Fuzhou, Fujian, Peoples R China

[22] Jiangxi Canc Hosp, Dept Gastroenterol, Nanchang, Jiangxi, Peoples R China

[23] Cent South Univ, Canc Hosp, Xiangya Sch Med, Dept Gastroenterol & Urol, Changsha, Hunan, Peoples R China

[24] Guizhou Med Univ, Dept Abdominal Oncol, Affiliated Hosp, Guiyang, Guizhou, Peoples R China

[25] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[26] Zhejiang Canc Hosp, Dept Abdominal Oncol, Hangzhou, Zhejiang, Peoples R China

[27] First Peoples Hosp Changde City, Dept Oncol, Changde, Hunan, Peoples R China

[28] Wenzhou Med Univ, Affiliated Hosp 1, Dept Radiotherapy, Wenzhou, Zhejiang, Peoples R China

[29] China Med Univ, Shengjing Hosp, Dept Med Oncol, Shenyang, Liaoning, Peoples R China

[30] Anhui Med Univ, Affiliated Hosp 1, Dept Med Oncol, Hefei, Anhui, Peoples R China

[31] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Med Oncol, Shanghai, Peoples R China

[32] First Affiliated Hosp, Bengbu Med Coll, Dept Med Oncol, Bengbu, Anhui, Peoples R China

[33] Shandong Canc Hosp & Inst, Dept Gastroenterol, Jinan, Shandong, Peoples R China

[34] Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, Nanning, Guangxi, Peoples R China

[35] Binzhou Peoples Hosp, Dept Med Oncol, Binzhou, Shandong, Peoples R China

[36] Quanzhou First Hosp, Dept Med Oncol, Quanzhou, Fujian, Peoples R China

来源：

CANCER COMMUNICATIONS | 2024年 / 44卷 / 08期

关键词：

D O I：

10.1002/cac2.12586

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：910 / 914

页数：5

共 50 条

[31] Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer
Zhang, Jing
Yang, Wenwei
Liu, Junbao
Wang, Nan
Ren, Zhaoying
Yang, Tingting
Xie, Gongli
Wu, Guifu
Sun, Yongkun
INVESTIGATIONAL NEW DRUGS, 2024, 42 (04) : 454 - 461
[32] Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients
Mitsukuni Suenaga
Satoshi Matsusaka
Masashi Ueno
Noriko Yamamoto
Eiji Shinozaki
Nobuyuki Mizunuma
Toshiharu Yamaguchi
Kiyohiko Hatake
Surgery Today, 2011, 41 : 1067 - 1074
[33] Predictors of the Efficacy of FOLFIRI plus Bevacizumab as Second-Line Treatment in Metastatic Colorectal Cancer Patients
Suenaga, Mitsukuni
Matsusaka, Satoshi
Ueno, Masashi
Yamamoto, Noriko
Shinozaki, Eiji
Mizunuma, Nobuyuki
Yamaguchi, Toshiharu
Hatake, Kiyohiko
SURGERY TODAY, 2011, 41 (08) : 1067 - 1074
[34] Irinotecan plus anlotinib or further in combination with penpulimab as second-line treatment of metastatic colorectal cancer (ZL-IRIAN)
Wang, Chenchen
Li, Wenhua
Zhu, Xiaodong
Geng, Qirong
Zhao, Xiaoying
Guo, Weijian
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[35] Phase II study of irinotecan and bevacizumab plus alternate day S-1 as second-line treatment in patients with metastatic colorectal cancer.
Tanaka, Chihiro
Matsuda, Chu
Kondo, Ken
Tokunaga, Yukihiko
Takahashi, Takao
Kosugi, Chihiro
Takemoto, Hiroyoshi
Iwamoto, Shigeyoshi
Oba, Koji
Sakamoto, Junichi
Mishima, Hideyuki
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[36] Antitumour activity of pemetrexed (Pem) and irinotecan (Iri) in second-line metastatic colorectal cancer (MCRC) patients: A multicenter phase II study
Louvet, C.
Andre, T.
Gamelin, E.
Hebbar, M.
Mabro, M.
Bennamoun, M.
De Gramont, A.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[37] A prospective, multicenter, observational study of bevacizumab in combined with chemotherapy as first-line or second-line treatment in Chinese metastatic colorectal cancer
Qin, Shukui
Deng, Yanhong
Bi, Feng
Liu, Tian Shu
Liu, Yunpeng
Zhang, Suzhan
Xu, Jianming
Shu Yongqian
Xu, Nong
Wu, Changping
Wang, Xin
Zhong, Haijun
Feng, Jifeng
He, Yulong
Yang, Jianwei
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[38] Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma
Haller, Daniel G.
Rothenberg, Mace L.
Wong, Alfred O.
Koralewski, Piotr M.
Miller, Wilson H., Jr.
Bodoky, Gyorgy
Habboubi, Nassir
Garay, Carlos
Olivatto, Luis O.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) : 4544 - 4550
[39] A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer
Jo, H.
Lee, M-S
Lee, Y-P
Kim, H.
Hong, J. Y.
Lee, J.
Park, S. H.
Park, J. O.
Park, Y. S.
Lim, H. Y.
Kang, W. K.
Kim, S. T.
CLINICAL ONCOLOGY, 2022, 34 (08) : E323 - E328
[40] A multicenter prospective non-randomized phase II study of bi-weekly Irinotecan vs Raltitrexed as first line chemotherapy in elderly patients with metastatic colorectal cancer
Grande, C.
Ramos, M.
Vazquez, S.
Candamio, S.
Huidobro, G.
Gonzalez, A.
Alvarez, E.
Jorge, M.
Almanza, C.
Casal, J.
ANNALS OF ONCOLOGY, 2004, 15 : 122 - 122

← 1 2 3 4 5 →